Melbourne-headquartered Telix Pharmaceuticals has expanded its United States presence with the acquisition of $73 million in proprietary technology and a research facility from Californian BioTech firm ImaginAb. Telix announced on Monday announced it was acquiring intellectual property for a pipeline of early-stage drug candidates that can target cancer cells and a facility in California staffed…

The post Telix Pharmaceuticals in $73m US IP, infrastructure buy-up appeared first on InnovationAus.com.

This post was originally published on InnovationAus.com.